{"id":80854,"date":"2026-04-20T20:49:54","date_gmt":"2026-04-20T20:49:54","guid":{"rendered":"https:\/\/diyhaven858.wasmer.app\/index.php\/in-early-trial-car-t-results-raise-hope-of-preventing-multiple-myeloma-in-high-risk-patients\/"},"modified":"2026-04-20T20:49:54","modified_gmt":"2026-04-20T20:49:54","slug":"in-early-trial-car-t-results-raise-hope-of-preventing-multiple-myeloma-in-high-risk-patients","status":"publish","type":"post","link":"https:\/\/diyhaven858.wasmer.app\/index.php\/in-early-trial-car-t-results-raise-hope-of-preventing-multiple-myeloma-in-high-risk-patients\/","title":{"rendered":"In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div data-author=\"angus-chen\">\n<p class=\"author-bio\">Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08.<\/p>\n<\/div>\n<div>\n<p>SAN DIEGO \u2014 Alison Cameron spent close to a decade fighting to keep myeloma under control. She\u2019d been diagnosed with smoldering multiple myeloma, a precursor to cancer, and spent years receiving infusions to keep it from progressing to active multiple myeloma. Now, after receiving CAR-T therapy, an aggressive immunotherapy, while on a trial, the 54-year old anesthesiologist is hoping the risk of cancer is gone for good.<\/p>\n<p>It\u2019s a reasonable hope, given the results of that trial, which researchers presented at the American Association for Cancer Research meeting here on Monday. All 20 patients who received the trial treatment no longer had any detectable myeloma cells in their body. That\u2019s a far deeper and more complete response than scientists typically expect when it comes to multiple myeloma, and it\u2019s prompting some experts to consider the possibility these patients have truly had active cancer permanently averted.<\/p>\n<p>Currently, there is only one approved therapy for high risk smoldering myeloma, an antibody therapy called Darzalex. Patients can remain on treatment for years, but without achieving these kinds of deep molecular responses, and many still progress within 5 years, said Ecaterina Dumbrava, a cancer researcher at MD Anderson Cancer Center who did not work on the study. \u201cThe results raise a very important question whether early immune interception can not only delay progression but redefine treatment goals. Can we talk about the word we always avoid, which is cure,\u201d she said.<\/p>\n<div class=\"restricted-content-breaker article\" aria-labelledby=\"restricted-story-heading\" aria-describedby=\"restricted-story-description\" checked=\"false\">\n<div class=\"restricted-content-breaker-bar\">\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? Log in<\/p>\n<\/p><\/div>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<div class=\"restricted-content-breaker-wrapper\">\n\t\t\t\t<span class=\"stat-paywall-archive\"><\/p>\n<p>\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t<\/span><\/p>\n<h2 id=\"restricted-story-heading\">This article is exclusive to STAT+ subscribers<\/h2>\n<h3 id=\"restricted-story-description\">Unlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/h3>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? Log in<\/p>\n<div class=\"restricted-content-breaker-cards\">\n<div class=\"slider-container\" aria-label=\"Subscription plan toggle\">\n\t\t\t\t\t\t<button type=\"button\" class=\"individual\" aria-pressed=\"false\">Individual plans<\/button><\/p>\n<p>\t\t\t\t\t\t<button type=\"button\" class=\"group\" aria-pressed=\"false\">Group plans<\/button>\n\t\t\t\t\t<\/div>\n<\/p><\/div>\n<p>\t\t\t\tView All Plans\n\t\t\t<\/p><\/div>\n<\/p><\/div>\n<div class=\"restricted-message-breaker\">\n<div class=\"restricted-content-wrapper\">\n<div class=\"restricted-content-message\">\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\tSubscribe\n\t\t\t\t\t\t\t\t\t<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":80855,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-80854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/04\/AdobeStock_251916243-1024x576.jpeg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/80854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=80854"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/80854\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/80855"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=80854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=80854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=80854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}